Effects of ectopic HER-2/neu gene expression on the COX-2/PGE2/P450arom signaling pathway in endometrial carcinoma cells: HER-2/neu gene expression in endometrial carcinoma cells

Journal of Experimental & Clinical Cancer Research

ZhiJuan Yu¹  YuanQi He¹  Cuicui Wang¹  Li Ma¹  XiaoXin Ma¹  Shu Li¹ 

[1] Department of Gynecology and Obstetrics, Shengjing Hospital of China Medical University, Shenyang, 110004, China

关键词: Endometrial carcinoma cell;    Estradiol;    P450arom;    COX-2;    HER-2/neu;   

Others  :  825384
DOI  :  10.1186/1756-9966-32-11

 received in 2012-12-07, accepted in 2013-02-23,  发布年份 2013

【 摘 要 】

Objectives

To investigate the role of HER-2/neu-mediated COX-2/P450arom signal in estrogen-dependent endometrial carcinoma.

Methods

The recombinant eukaryotic expression vector, pcDNA3.1-HER-2/neu, was constructed and transfect to Ishikawa endometrial carcinoma cells. The expression of COX-2 and P450arom in transfected cells were detected by real-time PCR and western blotting. The levels of estrogen in cell supernatants were detected by ELISA.

Results

Over-expression of HER-2/neu in transfected cells was confirmed by real-time PCR and western blotting. The levels of autocrine estrogen in transfected cells was significantly increased which combination with the enhancement of COX-2 and P450arom expression in transfected cells.

Conclusion

HER-2/neu induced the improvement of autocrine estrogen in endometrial carcinoma cell through triggering the COX-2/P450arom signal.

【 授权许可】

   
2013 Li et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Le J: Obstetrics and Gynecology [M]. 6th edition. China: Beijing: Beijing People’s Medical Publishing House; 2005:300.
• [2]Simeone AM, Li YJ, Broemeling LD: Cyclooxygenase-2 is essential for HER2/neu tosuppress N-(4-hydroxyphenyl) retinamide apoptotic effects in breast cancer cells. Cancer Res 2004, 64(4):1224-1228.
• [3]Wang SC, Lien HC, Xia W: Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 2004, 6(3):251-261.
• [4]Faltus T, Yuan J, Zimmer , Krämer A, Loibl S, Kaufmann M, Strebhardt K: Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia 2004, 6(6):786-795.
• [5]Tiseo M, Loprevite M, Ardizzoni A: Epidermalgrowth factor receptor inhibitors: a new prospective in the treatment of lung cancer. CurrMed Chem Anti-Canc Agents 2004, 4(2):139-148.
• [6]Kokay Y, Cohen JA: Stage-and tissue-specific expression of neu oncogene in rat development. Proc Natl Acad Sci USA 1987, 84:8498.
• [7]Xiao-xin M, Qing M: Expression of protein c-erbb-2 in endometrial diseases and clinical significance testis neoplasms. China Journal of Modern Medicine 2006, 16(4):550-552.
• [8]Yuan-qi HE, Xiao-xin MA, Shu LI: Effects of HER2 on COX-2/PGE2 /P450arom Signal Pathway in Nude Mice Endometial Model. The Journal of China Medical University 2010, 39(10):823-826.
• [9]Anastasi S, SALA G, Huiping C: Loss of R ALT/M IG -6expression in ER BB2-amplified breastcarcinom as enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. Oncogene 2005, 24:4540-4548.
• [10]Jager R, Friedrichs N, Heim I: Dual role of A P-2 gamma in ErbB-2-induced mammary tumorigenesis. Breast Cancer Res Treat 2005, 90(3):273-280.
• [11]Goncalves A, BRA DAC, Vire F: High-dose alkylating agents with autologous hem atopoietic stem cell support and trastuzumab in ERBB2 overexpressing metastatic breast cancer: afeasibility study. A nticancer Res 2005, 25(1B):663-667.
• [12]Essapen S, Thomas H, Green M: The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters. Int J On-col 2004, 24(2):241-248.
• [13]Half E, Broaddus R, Danenberg KD: HER −2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int J Cancer 2004, 108(4):540-548.
• [14]Ratna V, Mahitosh M, Liana A: Regulation of cyclooxygenase-2 pathway by HER-2 receptor. Oncogene 1999, 18(2):305-314.
• [15]Wang KH, Kao AP, Chang CC: Increasing CD44+/CD24(-) tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis. Mole Cancer 2010, 9:288. BioMed Central Full Text
• [16]Ohno S, Ohno Y, Suzuki N: Multiple roles of cy-clooxygenase-2 inendometrial cancer. Anticancer Res 2005, 25(6A):3679-3687.
• [17]Milczarek R, Klimek J: Aromatase–key enzyme of estrogen biosynthesis. Postepy Biochem 2005, 51(4):430-439.
• [18]Zeitoun KM, Takayama K, Michael MD: Stimulation of aromatase P450 promoter (II)activity in endometriosis and its inhibition in endometrium are regulated by competitive binding of SF-1 and COUP-TF to the same cis-acting element. Mol Endocrinol 1999, 13:239-253.
• [19]Chan SK, Hill ME, Gullick WJ: The role of the epidermal growth factor receptor in breast cancer. J Mammary Gland Biol Neoplasia 2006, 11(1):3-11.
• [20]Livasy CA, Reading FC, Moore DT: EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol Oncol 2006, 100(1):101-106.
• [21]Ejskjaer K, Sorensen BS, Poulsen SS: Expression of the epidermal growth factor system in endometrioid endometrial cancer. Gynecol Oncol 2007, 104(1):158-167.